Aqsens Health Oy and Children’s Hospital at HUS (Helsinki University Hospital) have started a collaboration project for testing a new method for the detection and classification of inflammatory bowel disease, IBD. In the project parties will investigate the potential of Aqsens Heath’s E-TRF method using fecal sample material together with clinical research expertise and comparisons to full clinical analysis. Parties are expecting to publish initial results in November 2019.
Inflammatory Bowel Diseases, namely Crohn’s disease and ulcerative colitis, are a growing health burden in Finland and in other developed economies. IBD affects as many as over 10 million people worldwide and equally among men and women. It can occur at any age, but more often among young adults between the ages of 15 and 35. Despite considerable research work, the causes of the disease is still unknown but studies indicate that the inflammation involves a complex interaction of factors like: the genes inherited, the immune system, and further something in the environment in which you live also appears to play a role. IBD is more common in developed countries than emerging economies, in urban than rural areas, and in northern versus southern climates.
Research on IBD has a long history in Finland, and having the opportunity to work with new innovative methods can open new discoveries and opportunities for IBD research, says Kaija-Leena Kolho, professor of Pediatrics at the University of Helsinki and Helsinki Children’s hospital. One aim of the project is to find complementary test for existing ones and hence improving accurate early stage diagnosis and therapy initiation.
“The pediatric research group has collected a unique and comprehensive sample set with all relevant metadata for research. Therefore collaboration is a privilege for us and I am really glad that our E-TRF method and initial results has convinced them to conduct this research study with us, says Timo Teimonen, the CEO of Aqsens Health Oy,
In the project Aqsens Health will run presentative selection and amount of E-TRF tests against clinically diagnosed bowel diseases and compare results with industry gold standards. In parallel parties will conduct complementary tests using established scientific methods like mass spectrometry (MS) and Nuclear magnetic resonance spectroscopy (NMR) for discovering causality in the findings. Aim of this research study is to find new indicators for IBD and also its correlation to other human health factors.
Aqsens Health, Timo Teimonen (+358 40 585 3105) Professor of Pediatrics, Kaija-Leena Kolho (+358 50 427 4858)
About Aqsens Health
Aqsens Health has developed a non-invasive screening and diagnosis method (E-TRF and Machine Learning) to analyse microbiota, urine and saliva, and very small-scale metabolic changes therein. The company’s focus is on non-invasive screening of health disorders having major impact for both individual patients and society.